Aspirin and Bladder Cancer; Oncology Workforce Shortage; ‘Exploding Immune Cells’

A large Danish study suggests that aspirin use may indirectly help uncover asymptomatic bladder cancer. (Journal of Internal Medicine)

A concerning number of deaths and lack of survival benefit in a confirmatory trial have raised questions about the approval status for the antibody-drug conjugate loncastuximab tesirine (Zynlonta) in diffuse large B-cell lymphoma. (BioSpace)

Long-time FDA official Richard Pazdur, MD, who established the agency’s Oncology Center of Excellence, has joined the board of directors for Friends of Cancer Research.

“A global crisis”: The shortage of cancer care personnel could reach 100 million positions worldwide over the next 25 years, according to a Lancet Oncology Commission report.

An international research collaboration has identified a group of proteins that might predict lung cancer up to 5 years before it becomes apparent to current diagnostic methods — and an existing drug may reduce levels of those proteins and potentially prevent the cancer. (New York Times)

Could a simple probiotic help reduce the risk of esophageal cancer related to acid reflux? (University of Central Florida)

The FDA approves more orphan drugs with cancer or pediatric indications than does the European Medicines Agency. (Regulatory Affairs Professionals Society)

Targeted radiation therapy may increase CAR T-cell therapy durability to improve treatment of melanoma, lung cancer, and other solid tumors. (Mount Sinai)

An expanded partnership between Cencora and Gilead Sciences could make the latter’s CAR T-cell therapies more widely available to U.S. patients. (Fierce Pharma)

An oncologist describes how artificial intelligence (AI) helped him deal with the “cognitive load problem” of a busy clinical practice. (Oncology News Central)

Use of an AI program for mammogram analysis has improved the ability to identify high-risk patients and reduce the time to follow-up imaging to confirm the diagnosis. (University of California San Francisco)

Laboratory-created flatworms demonstrated an “explosive new type of immune cell” that protects the organisms from internal threats. Could the discovery be adapted for therapeutic use in humans? (Stanford Report)